menu
    • menu
    [{"orgOrder":0,"company":"Modra Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Docetaxel","moa":"||Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Modra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Modra Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Modra Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Modra Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Docetaxel","moa":"||Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Modra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Modra Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Modra Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Modra Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Docetaxel","moa":"||Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Modra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Modra Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Modra Pharmaceuticals \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Modra Pharmaceuticals

    Menu

    Modra Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Modra Pharmaceuticals

                            Netherlands arrow
                            IFT FIRST
                            Not Confirmed

                            Modra Pharmaceuticals

                            Netherlands arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Docetaxel,Ritonavir

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Modra Pharmaceuticals Announces U.S. Patent Issuance for ModraDoc006/r

                            Details : ModraDoc006/r is an oral tablet formulation of docetaxel co-administered with ritonavir, designed to be an effective anti-cancer therapeutic which can be taken at home and which eliminates or reduces serious, treatment-limiting side effects.

                            Product Name : ModraDoc006/r

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            March 16, 2023

                            Lead Product(s) : Docetaxel,Ritonavir

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Modra Pharmaceuticals

                            Netherlands arrow
                            IFT FIRST
                            Not Confirmed

                            Modra Pharmaceuticals

                            Netherlands arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Docetaxel,Ritonavir

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Modra Pharmaceuticals Presents In-Depth Data Analysis from Lower Dose Cohort in Phase 2b Study of Oral Taxane ...

                            Details : ModraDoc006/r is an oral tablet formulation of docetaxel co-administered with ritonavir, a boosting agent which enhances bioavailability. In a total of 101 patients enrolled, ModraDoc006/r demonstrated a similar efficacy and an improved tolerability prof...

                            Product Name : ModraDoc006/r

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            May 27, 2022

                            Lead Product(s) : Docetaxel,Ritonavir

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Modra Pharmaceuticals

                            Netherlands arrow
                            IFT FIRST
                            Not Confirmed

                            Modra Pharmaceuticals

                            Netherlands arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Docetaxel,Ritonavir

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Modra Pharmaceuticals to Present New Phase 2b Data at the 2022 ASCO General Annual Meeting on ModraDoc006/r, a...

                            Details : ModraDoc006/r (docetaxel) is a proprietary boosted taxane therapy based on docetaxel, an intravenously administered therapy, that is very broadly used in a variety of tumor types.

                            Product Name : ModraDoc006/r

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            May 23, 2022

                            Lead Product(s) : Docetaxel,Ritonavir

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth